| Teclistamab studied in …STUDIED_INderived57 of 57show fewer |
|---|
| → studied in | NCT07605416Phase 2 · recruiting Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial · 57 trials list this drug (52 active) | — | — | Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06425991Phase 1 · active not recruiting A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948084Phase 2 · recruiting Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03145181Phase 1 · active not recruiting Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108195Phase 1 · active not recruiting A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083169Phase 3 · active not recruiting A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05338775Phase 1 · active not recruiting A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552222Phase 3 · recruiting A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572229Phase 2 · active not recruiting Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208150Phase 3 · active not recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06477783recruiting Study on the Clinical Efficacy of Teclistamab and Talquetamab · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577025Phase 2 · active not recruiting A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030517Phase 4 · active not recruiting A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07258511Phase 3 · recruiting A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518186Phase 3 · recruiting A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465316Phase 1 · recruiting Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332507Phase 1 · recruiting Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma · 57 trials list this drug (52 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791498Phase 2 · not yet recruiting Teclistamab In Waldenstrom's Macroglobulinemia · 57 trials list this drug (52 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07105059Phase 1 · recruiting A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07463807Phase 1/Phase 2 · recruiting Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638683Phase 2 · recruiting A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). · 57 trials list this drug (52 active) | — | — | Multiple Myeloma,AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04557098Phase 2 · active not recruiting A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740486Phase 3 · not yet recruiting A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07728188Phase 3 · not yet recruiting A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649695Phase 2 · active not recruiting A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis · 57 trials list this drug (52 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855121recruiting The Norwegian Immunotherapy in Multiple Myeloma Study · 57 trials list this drug (52 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia,AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05469893Phase 2 · recruiting Immuno-PRISM (PRecision Intervention Smoldering Myeloma) · 57 trials list this drug (52 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649525Phase 3 · recruiting Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level · 57 trials list this drug (52 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07110844Phase 2 · recruiting Teclistamab-Daratumumab in AL Amyloidosis · 57 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07657312Phase 2 · recruiting Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671287Phase 3 · not yet recruiting GMMG-HD11/DSMM XXI/64007957MMY3010 · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068597Phase 1/Phase 2 · recruiting Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies · 57 trials list this drug (52 active) | — | — | Multiple Myeloma,Non-Hodgkin Lymphoma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04696809Phase 1/Phase 2 · completed A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06171685Phase 2 · active not recruiting MMRC Horizon One: RRMM (MMRC-099) · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05243797Phase 3 · recruiting Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07581704Phase 1 · recruiting Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06993675Phase 2 · recruiting Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05849610Phase 2 · active not recruiting Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma · 57 trials list this drug (52 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05972135Phase 2 · recruiting Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07107529Phase 2 · recruiting Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572515Phase 3 · active not recruiting A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353022Phase 2 · active not recruiting Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06100237Phase 2 · recruiting Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04586426Phase 1/Phase 2 · active not recruiting A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05695508Phase 2 · recruiting GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05161598no longer available Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06251076Phase 4 · recruiting Plan Development for Giving Teclistamab in the Outpatient Setting · 57 trials list this drug (52 active) | — | — | Malignant Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06588660Phase 1 · terminated ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07079423Phase 2 · recruiting Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis · 57 trials list this drug (52 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05463939approved for marketing Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06935162Phase 2 · recruiting Teclistamab in Previously Treated AL Amyloidosis · 57 trials list this drug (52 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06699394NA · recruiting Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis · 57 trials list this drug (52 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06880601Phase 2 · not yet recruiting Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06758375Phase 2 · recruiting Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06352866Phase 2 · withdrawn Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06505369Phase 2 · recruiting Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients · 57 trials list this drug (52 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |